Ann & Robert H. Lurie Children’s Hospital of Chicago launched a newborn screening awareness campaign, with signage on public transit and billboards across Chicago urging parents to contact their child ...

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly diagnosed with pulmonary fibrosis feel supported during this time via a new ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Women are being forced to consider “flying or dying” as they wait up to four months to get a mammogram following the ...

Cystic fibrosis, a genetic disease that attacks the lungs, affects roughly 1 in 3,000 people, and cystic fibrosis-related diabetes (CFRD) is its most common complication, a rare and unique type ...

Research is still in the early stages of how vaping affects lungs – but worrying conditions, like ‘popcorn lung’, are on the rise. Dr Stephen Broderick, of John Hopkins Medicine, has now ...

Paul Alexander, AKA 'the man in the iron lung', was able to live for more than 70 years inside the medical contraption prior to his death. Polio may have been eradicated from most of the world ...

A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the disease returning by a third. Patients taking the drug were also 32 per cent ...

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients ... In the lungs, it causes the buildup of mucus ...

Breathing is something we do every moment, yet we rarely think about the health of our lungs until a problem arises. With rising pollution levels, smoking, and other environmental toxins ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...